Knocking out a certain gene or reducing its expression by using an enzyme inhibitor may provide a new avenue for treating Alzheimer's disease.
Years of flat funding from the National Institutes of Health plus across-the-board federal spending cuts known as sequestration could have deleterious effects for cancer research, says a new study by the American Association for Cancer Research.
Pluristem Therapeutics unveiled new preclinical results for its placental-expanded cell therapy showing an early beneficial effect on tendon healing after injury.
A class of FDA-approved antipsychotic drugs may provide a new approach to treating the most aggressive form of primary brain cancer, glioblastoma.
As the threat of antibacterial resistance rises, new antibiotics are sorely needed as microbes mutate and get better at outsmarting current therapies available for bacterial infections.
The National Institute of Allergy and Infectious Diseases has awarded a 7-year, $9.8 million grant to develop an AIDS vaccine to four Seattle-based research organizations and Rockefeller University.
Announced earlier this week, President Barack Obama's proposed budget for 2015 includes $30.4 billion for the National Institutes of Health, a slight increase of $211 million over this fiscal year's budget.
Oregon Health & Science University is opening a new Center for Embryonic Cell and Gene Therapy to study experimental treatments for Parkinson's disease, multiple sclerosis and a range of other conditions caused by diseased or injured cells in the human body.
International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
A new discovery that explains how the body's immune system makes a potent antibody that blocks HIV infection may be an important step toward developing a vaccine against the virus.
Researchers think they've discovered why previous efforts at targeting the enzyme LTA4 hydrolase, a key player in the body's inflammatory response, have failed and produced a new molecule that may prove more successful.
An experimental antiviral compound developed by BioCryst Pharmaceuticals and the U.S. Army Medical Research Institute of Infectious Diseases provided complete protection in monkeys against Marburg virus and Ebola, two highly virulent pathogens with no effective treatments.
A supplement that activates a protein involved in metabolic balance showed an extension in lifespan and improvement in the overall health of mice, according to a new study.
Increased brain cell activity seems to boost levels of the protein tau, a hallmark of Alzheimer's disease, according to researchers. The link could help advance efforts to treat Alzheimer's disease and other neurodegenerative disorders.
The NIH has added a huge amount of medical data--from a diverse group of more than 78,000 people with an average age of 63--to Genetic Epidemiology Research on Aging, one of the nation's largest and most diverse genomics projects.
The Department of Defense has selected Denmark's Bavarian Nordic to develop a vaccine against two potential biological pathogens deemed to be threats to national security.
A new vaccine developed by German researchers may be effective against a certain type of skin cancer in organ transplant patients caused by papillomavirus.
Researchers have found a way to transform skin cells into fully functioning mature liver cells that grow on their own after being transplanted into mice.
Last month AstraZeneca said it is shuttering an Indian research site as it moves away from neglected diseases to focus on areas with more potential for growth. The move is a hit to global tuberculosis R&D, which received $10 million from AstraZeneca in 2012.
Some say the recent allegations about a potential stem cell breakthrough unveiled in January by a major Japanese research institution represent a larger problem of irreproducibility in early science research. But others, like Edward Ahn, managing director and chief science officer of Cambridge, MA-based MedCap Advisors, think we shouldn't jump to conclusions quite yet.